NTRK1 and Merkel cell skin cancer: Janus kinases (JAK) are the intracellular non-receptor tyrosine kinases of the JAK-STAT pathway. A World Health Organization (WHO) international database query identified a disproportionate increase in MCC diagnoses among patients taking the JAK inhibitors ruxolitinib, tofactinib, and baricitinib.